title: A prospective trial comparing oocyte donor ovarian response and recipient pregnancy rates between suppression with gonadotrophin-releasing hormone agonist (GnRHa) alone and dual suppression with a contraceptive vaginal ring and GnRH.
abstract: BACKGROUND
  Contraceptive treatment before gonadotrophin-releasing hormone agonist administration presents advantages in women with a tendency to hyper-response and simplifies donor-recipient treatment synchronization. This study compares response to gonadotrophin stimulation under hypophyseal suppression in oocyte donors with or without vaginal contraceptive pretreatment.
  
  
  METHODS
  One hundred and ninety oocyte donors were recruited in a single centre and prospectively assigned to one of two treatment groups, according to the day of the week menstruation initiated: Group VC-, no prior vaginal contraceptive and Group VC+, prior vaginal contraceptive.
  
  
  RESULTS
  VC+ patients presented a significantly higher cancellation rate, lower plasma estradiol levels and fewer follicles >12 mm on the day of hCG, versus the VC- group. Number of oocytes recovered was significantly lower in the VC+ group. All the cases of severe ovarian hyperstimulation syndrome (SOHSS) were in the VC- group. Pregnancy rates by embryo transfer to synchronic recipients were similar between VC+ and VC- (59.5 versus 57.9%, respectively).
  
  
  CONCLUSIONS
  Vaginal contraceptive pretreatment resulted in a higher ovarian suppression, whereas SOHSS rate was lower than in donors who did not receive pretreatment. There were no differences in pregnancy rates between the two groups of synchronic oocyte recipients.
authors.affiliation: Servicio de Medicina de la Reproducción, Institut Universitari Dexeus, Barcelona, Spain. pacmar@dexeus.com
authors.forename: F
authors.initials: F
authors.lastname: Martínez
authors.forename: M
authors.initials: M
authors.lastname: Boada
authors.forename: B
authors.initials: B
authors.lastname: Coroleu
authors.forename: E
authors.initials: E
authors.lastname: Clua
authors.forename: N
authors.initials: N
authors.lastname: Parera
authors.forename: I
authors.initials: I
authors.lastname: Rodríguez
authors.forename: P N
authors.initials: PN
authors.lastname: Barri
mesh_terms: D000328:Adult; D003267:Contraception / Q000379:methods*; D003274:Contraceptive Devices, Female; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists* / Q000627:therapeutic use; D006801:Humans; D018587:Oocyte Donation / Q000379:methods*; D016471:Ovarian Hyperstimulation Syndrome / Q000209:etiology; D010062:Ovulation Induction / Q000379:methods*; D011247:Pregnancy; D018873:Pregnancy Rate
chemical_list: D007987:Gonadotropin-Releasing Hormone